Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlaxoSmithKline plc
  6. Summary
    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
06/07/2021 06/08/2021 06/09/2021 06/10/2021 06/11/2021 Date
1352.4(c) 1351.8(c) 1380.4(c) 1396.6(c) 1403.4(c) Last
3 510 959 4 625 710 7 305 888 6 692 034 5 444 955 Volume
-0.13% -0.04% +2.12% +1.17% +0.49% Change
More quotes
Financials
Sales 2021 33 199 M 46 839 M 46 839 M
Net income 2021 3 809 M 5 374 M 5 374 M
Net Debt 2021 21 523 M 30 366 M 30 366 M
P/E ratio 2021 18,8x
Yield 2021 5,67%
Sales 2022 34 915 M 49 260 M 49 260 M
Net income 2022 4 693 M 6 621 M 6 621 M
Net Debt 2022 20 235 M 28 549 M 28 549 M
P/E ratio 2022 15,2x
Yield 2022 4,22%
Capitalization 70 225 M 99 056 M 99 078 M
EV / Sales 2021 2,76x
EV / Sales 2022 2,59x
Nbr of Employees 94 066
Free-Float 92,3%
More Financials
Company
GlaxoSmithkline plc is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (50%): intended for respiratory diseases (64.9% of net sales), HIV infection (28.6%), immune system disorders (4.3%) ) and cancer (2.2%); - OTC and parapharmaceutical medicine (29.4%); - vaccines (20.5%); - other (0.1%). Net sales are distributed geographically as... 
Sector
Pharmaceuticals
Calendar
06/23 | 09:00amInvestor Meeting - Day - 1
More about the company
Ratings of GlaxoSmithKline plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about GLAXOSMITHKLINE PLC
06/11GLAXOSMITHKLINE ( '') (FORM 6 K  : GlaxoSmithKline plc (the 'Company') (Form 6-K..
PU
06/11GLAXOSMITHKLINE  : Deutsche Bank Lifts GlaxoSmithKline's PT, Keeps Sell Rating
MT
06/09GLAXOSMITHKLINE ( '') (FORM 6 K  : GlaxoSmithKline plc (the 'Company') (Form 6-K..
PU
06/09GSK consumer arm confident that growth, cash flow will help with debt
RE
06/08GLAXOSMITHKLINE  : Progentec Sign Research Deal to Assess Proteomics, Digital He..
MT
06/04GLAXOSMITHKLINE  : GSK recommends shareholders reject mini-tender offer by TRC C..
PU
06/04GLAXOSMITHKLINE  : Urges Shareholders to Rebuff TRC 'Mini-Tender' Offer
MT
06/04GlaxoSmithKline Advises ADS Holders to Reject TRC Capital Tender Offer
DJ
06/04U.S. authorizes Regeneron's COVID-19 antibody therapy for injection
RE
06/04GLAXOSMITHKLINE  : UBS remains Neutral
MD
06/04Regeneron's Covid-19 Drug Is Authorized for Injection
DJ
06/03Breast-Cancer Pill Reduced Recurrence, Death in Early-Stage Patients, Study F..
DJ
06/03REFILE-UPDATE 4-Biden outlines plan to quickly share 25 mln COVID-19 vaccines..
RE
06/02Hedge fund Elliott Management owns big Dropbox stake, holds discussions
RE
06/02Hedge fund Elliott Management owns big Dropbox stake, holds discussions
RE
More news
News in other languages on GLAXOSMITHKLINE PLC
06/11WOCHENVORSCHAU : Termine bis 25. Juni 2021
06/11MÄRKTE EUROPA/Gut behauptet - fallende Renditen stützen
06/11WOCHENVORSCHAU : Termine bis 24. Juni 2021
06/10WOCHENVORSCHAU : Termine bis 23. Juni 2021
06/04Glaxosmithkline rät ADS-Inhabern, TRC-Mini-Tender-Offerte abzulehnen
More news
Analyst Recommendations on GLAXOSMITHKLINE PLC
More recommendations
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Average target price 1 512,09 GBX
Last Close Price 1 403,40 GBX
Spread / Highest target 38,9%
Spread / Average Target 7,74%
Spread / Lowest Target -23,8%
EPS Revisions
Managers and Directors
NameTitle
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE PLC4.58%99 056
JOHNSON & JOHNSON4.82%434 405
ROCHE HOLDING AG10.68%328 612
PFIZER, INC.9.07%224 747
NOVARTIS AG-0.39%208 035
ABBVIE INC.7.72%203 857